Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;7(1):29-41.
doi: 10.1177/2045125316672136. Epub 2016 Oct 17.

Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole

Joshua S Frankel  1 , Thomas L Schwartz  2
Affiliations
Review

Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole

Joshua S Frankel et al. Ther Adv Psychopharmacol. 2017 Jan.

Abstract

Background: Brexpiprazole and cariprazine are the latest US Food and Drug Administration approved atypical antipsychotics available in the United States. Both function as partial agonists of the dopamine-2 receptor (D2R), a mechanism of action shared with aripiprazole. However, all three differ in their affinities for the D2R as well as for serotonin receptors (5-HTRs). This paper seeks to delineate these pharmacodynamic and clinical differences amongst the three dopamine partial agonist atypical antipsychotic drugs.

Methods: PubMed and clinicaltrials.gov searches were used to generate preclinical and clinical evidence for review. Data derived from animal models and human subjects were used to provide insight on clinical mechanisms and adverse effect potentials. Clinical trial data were reviewed to compare clinical efficacy and adverse effects.

Results: Efficacies among the three drugs are comparable for their shared indications. Side-effect profile and underlying pharmacodynamic mechanism of action for each drug may differ.

Conclusion: Partial agonism of the D2R is a similarity of the three drugs reviewed. Each drug varies in affinity for both the D2R and a diverse group of 5-HTRs, generating a distinct profile of clinical indications and adverse effects for each.

Keywords: antipsychotic; aripirazole; brexpiprazole; cariprazine; dopamine partial agonist.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Actavis (2015) VRAYLAR™ (Cariprazine) Capsules, for Oral Use (prescribing Information). Available at: http://pi.actavis.com/data_stream.asp?product_group=2028&p=pi (accessed 6 December 2015).
    1. Adams D., Close S., Farmen M., Downing Ann Catherine M., Breier A., Houston J. (2008) Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately Caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 23: 267–274. - PubMed
    1. Alkermes (2015) ARISTADA™ (Aripiprazole Lauroxil) Extended Release Injectable Suspension for Intramuscular Use (Prescribing Information). Available at: http://www.aristada.com/hcp/ARISTADA-prescribing-information.pdf (accessed 6 December 2015).
    1. Andrezine R., Josiassen R., Marcus R., Oren D., Manos G., Stock E., et al. (2006) Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 188: 281–292. - PubMed
    1. Berman R., Marcus R., Swanink R., McQuade R., Carson W., Corey-Lisle P., et al. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843–853. - PubMed